Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AC0058
AC0058TA · 1 trial · 1 indication
Frequency and severity of AEs and serious AEs
| Arm | Type | Description |
|---|---|---|
| AC0058TA | EXPERIMENTAL | Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA |
| Placebo capsules | PLACEBO_COMPARATOR | Drug: Placebo capsules |
| Name | Type | Description |
|---|---|---|
| AC0058TA | DRUG | 50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA |
| Placebo capsules | DRUG | Placebo capsules |
Inclusion Criteria: * Male or female, of any ethnic origin, age ≥18 and ≤65 years of age; * BMI ≥18.5 and ≤32.0 kg/m2; * Medical history without major pathology and determined to be in good health with no clinically significant findings as assessed by the Investigator; * All clinical laboratory tes...
AC0058TA is an investigational small molecule drug being developed by Scilex Holding Company. It has been studied in a Phase 1 clinical trial in healthy adult volunteers in the United States. The specific therapeutic indication for AC0058TA has not been publicly disclosed.
AC0058TA is being developed by Scilex Holding Company, which trades under the ticker symbol SCLX. Scilex is the sponsor of the clinical program evaluating this small molecule asset.
AC0058TA is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA.
AC0058TA has been evaluated in one clinical trial, NCT02847325, titled Study of AC0058TA in Healthy Male and Female Subjects. The Phase 1 trial enrolled 56 healthy volunteers in the United States, was randomized, double-blind, and placebo-controlled, and has been completed.
The Phase 1 trial of AC0058TA, NCT02847325, was a randomized, double-blind, placebo-controlled study conducted in the United States. It enrolled 56 healthy male and female volunteers aged 18 years and older. The trial has been completed.